Holen Sie sich die Stockscreener-App
0.9259
2.80%
-0.0412
Schlusskurs vom Vortag:
$0.9671
Offen:
$0.9667
24-Stunden-Volumen:
603.44K
Relative Volume:
1.50
Marktkapitalisierung:
$79.69M
Einnahmen:
$38.70M
Nettoeinkommen (Verlust:
$-142.66M
KGV:
-0.3404
EPS:
-2.72
Netto-Cashflow:
$-98.18M
1W Leistung:
-10.47%
1M Leistung:
-36.91%
6M Leistung:
-41.61%
1J Leistung:
-18.26%
1-Tages-Spanne:
$0.92
$0.9802
1-Wochen-Bereich:
$0.92
$1.09
52-Wochen-Spanne:
$0.92
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
Firmenname
Adicet Bio Inc
Sektor
Branche
Telefon
617-482-2333
Adresse
131 DARTMOUTH STREET, BOSTON
Vergleichen Sie ACET mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ACET | 0.9259 | 79.69M | 38.70M | -142.66M | -98.18M | -2.72 |
| VRTX | 450.34 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.32 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.38 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-06-27 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-03-31 | Eingeleitet | SMBC Nikko | Outperform |
| 2022-03-08 | Eingeleitet | Truist | Buy |
| 2022-03-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-04-08 | Eingeleitet | Guggenheim | Buy |
| 2020-11-04 | Eingeleitet | B. Riley Securities | Buy |
| 2020-10-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-16 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Adicet Bio Inc Aktie (ACET) Neueste Nachrichten
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins lupus nephritis trial, eyes other diseases By Investing.com - Investing.com UK
Adicet Bio Launches Phase 1 Trial for Lupus Drug with FDA Fast Track Status | ACET Stock News - StockTitan
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Adicet Bio's ADI-001 Shows Breakthrough CAR T Cell Results in Autoimmune Treatment Study | ACET Stock News - StockTitan
Adicet Bio amends loan terms with PacWest Bank - Investing.com India
RA Capital Management, L.P. Expands Stake in Adicet Bio Inc - GuruFocus.com
Adicet Bio To Present At Guggenheim Securities Healthcare Innovation Conference; Webcast At 3:00 PM - Nasdaq
FY2024 EPS Estimates for Adicet Bio Lowered by HC Wainwright - MarketBeat
HC Wainwright Decreases Earnings Estimates for Adicet Bio - Defense World
Wedbush Reiterates “Outperform” Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits Estimates - MarketBeat
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio to Present Breakthrough CAR T Cell Therapy at ACR Convergence 2024 | ACET Stock News - StockTitan
Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio shares maintain Neutral rating after FDA IND amendment - Investing.com India
Adicet Bio shares maintain Neutral rating after FDA IND amendment By Investing.com - Investing.com Australia
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Yahoo Finance
FDA greenlights Adicet Bio's trial expansion for autoimmune diseases - Investing.com
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 11.0% in September - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat
Adicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.com - MarketBeat
Millennium Management LLC Adjusts Stake in Adicet Bio Inc - GuruFocus.com
Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio Inc’s Shares Reel: 36.70% Quarterly Revenue Decline Amid 122.78M Market Cap - The InvestChronicle
Did Adicet Bio Inc (ACET) perform well in the last session? - US Post News
Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St
Recent Insider Activity Suggests Potential Gains for Adicet Bio Inc (ACET) - Knox Daily
Adicet Bio stock maintains neutral rating amid lupus nephritis trial - Investing.com
Stonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy - Clinical Trials Arena
Stonepine Capital Management LLC Increases Stake in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire
Adicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Guggenheim - MarketBeat
Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace
Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks
Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Finanzdaten der Adicet Bio Inc-Aktie (ACET)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):